Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
RESPONSE TO AMENDMENT
Status of Application/Amendments/claims
Applicant’s amendment filed June 16, 2026 is acknowledged. Claims 12-14, 18, 20, 22, 24, 32-34, 36-40 and 43-44 are canceled. Claims 1, 5, 10, 19, 21 and 42 are amended. Claims 1-11, 15-17, 19, 21, 23, 25-31, 35 and 41-42 are pending in this application. Claims 23, 30 and 41 are withdrawn without traverse (filed 12/08/2025) from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on July 28, 2025.
3. Claims 1-11, 15-17, 19, 21, 25-29, 31, 35 and 42 are under examination with respect to amino acid residues 149-157 of SEQ ID NO:1 or amino acid residues on a TREM2 protein corresponding to aa 149-157 of SEQ ID NO:1 for epitope; SEQ ID NOs:34-35, 31 and 41, 33 and 32 for HVR-H1-H3 and HVR-L1-L3; SEQ ID NOs: 27 and 30 for HVR and LVR; SEQ ID NOs: 44 and 47 for HC and LC and ALSP for disease in this office action.
4. Applicant’s arguments filed on June 16, 2026 have been fully considered but they are not deemed to be persuasive for the reasons set forth below.
Specification
5. The objection to the specification is withdrawn in response to Applicant’s amendment to the specification and arguments on p. 11-12 of the response.
Claim Rejections/Objections Withdrawn
6. The objection to claims 1-11, 15-16, 19, 21, 31, 35, and 42 is withdrawn in response to Applicant’s amendment to the claims.
The rejection of claim 21 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite is withdrawn in response to Applicant’s amendment to the claims.
The rejection of claims 32 and 39 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement is moot because the claims are canceled.
The rejection of claims 32 and 39 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement is moot because the claims are canceled.
The provisional rejection of claims 1-11, 15-17, 19, 21, 25-29, 31-32, 35, 39 and 42 on the ground of nonstatutory double patenting as being unpatentable over claims 2-3, 5-6, 17,19, 22-23, 37, 39-40, 44,46, 48, 51-52, 54, 70 and 86 of copending Application No. 17/916728 is moot because Application No. 17/916728 was abandoned.
Claim Rejections/Objections Maintained
In view of the amendment filed on June 16, 2026, the following rejections are maintained.
Claim Rejections - 35 USC § 112
7. The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 10-11 and 42 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. The rejection is maintained for the reasons of record and the reasons set forth below.
Response to Arguments
On p. 13 of the response, Applicant argues that the rejection has been overcome in view of amendment to the claims.
Applicant’s arguments, see p. 13 of the response filed 06/16/2026, with respect to the rejection(s) of claim(s) 12 under 35 U.S.C. 112(b) have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of amendment to claims 10-11 and 42. Based on MPEP§2171-MPEP§2173, claims 10-11 and 42 are indefinite because:
i. The term "increasing activity of ….” recited in item f. of claim 10, the term “increased survival of ….” recited in the item g. of claim 10, the term “increasing memory” recited in the item i. of claim 10 or the term “reducing cognitive deficit” recited in the item j. of claim 10, the term “decreases plasma levels…” recited in item (b) of claim 11 is a relative term which renders the claim indefinite. The term "increasing activity of ….”, the term “increased survival of ….”, the term “increasing memory” or the term “reducing cognitive deficit” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Applicant fails to set forth the metes and bounds of what is encompassed within the definition of the term "increasing activity of ….”, the term “increased survival of ….”, the term “increasing memory” or the term “reducing cognitive deficit”. Since the metes and bounds are unknown, a skilled artisan cannot envision what would be considered as "increasing activity of ….”, “increased survival of ….”, “increasing memory” or “reducing cognitive deficit” recited in the claims. Thus the claims are indefinite.
ii. The term “modulation….” recited in item d. of claim 10 is indefinite. Applicant fails to define the word “modulation” recited in the claim. A compound or antibody can either enhance or inhibit production or function of recited pro-inflammatory mediators and subsequently treat the claimed ALSP or pediatric-onset leukoencephalopathy. It is unclear whether an agent/anti-TREM2 antibody can enhance or inhibit the production or activity of recited pro-inflammatory mediators and thereby treat the claimed ALSP or pediatric-onset leukoencephalopathy, and thus the claims are indefinite.
iii. Claim 42 recites “monitoring a treatment of an individual being administered an anti-TREM2 antibody…..” and “wherein the antibody induces one or more TREM2 activities”, which renders the claim indefinite. It is unclear what one or more TREM2 activities are. Applicant fails to define what the claimed one or more TREM2 activities are; and it is also unclear how the claimed one or more TREM2 activities relate to the treatment and how to monitor. The claim or the disclosure fails to set for the metes and bounds of what is encompassed within the definition of “one or more TREM2 activities” and their relationship with “the change” in the level of CSFR1. Thus the artisan cannot envision what Applicant intended to monitor, which renders the claim indefinite.
Accordingly, the rejection of claims 10-11 and 42 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite is maintained.
Claim Rejections - 35 USC § 112
8. The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-11, 15-17, 19, 21, 25-29, 31, 35 and 42 stand rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The rejection is maintained for the reasons of record and the reasons set forth below.
Claims 1-11, 15-17, 19, 21, 25-29, 31 and 35 as amended are drawn to a method for treating a CSF1R-deficient disease comprising administering to an individual in need thereof a therapeutically effective amount of an anti-TREM2 agonist antibody, wherein the CSF1R is adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) or pediatric-onset leukoencephalopathy.
Claim 42 is drawn to a method of monitoring a treatment of an individual being administering an anti-TREM2 agonist antibody, comprising measuring a level of CSF1R in a sample from the individual before and after the individual has received one or more doses of the anti-TREM2 agonist antibody that induces one or more TREM2 activities.
Briefly, claims 1-11, 15-17, 19, 21, 25-29, 31 and 35 are directed to using a structurally and functionally undefined anti-TREM2 agonist antibody or a structurally and functionally undefined anti-TREM2 agonist antibody binding 149-157 of SEQ ID NO:1 or one or more amino acid residues recited in claim 19 for treating ALSP or pediatric-onset leukoencephalopathy. Claim 42 is directed to using a structurally and functionally undefined anti-TREM2 agonist antibody for treating undefined condition in an undefined individual. The specification provides insufficient guidance to enable a skilled artisan to practice the claimed methods without undue experimentation because:
i. There is no well-established structural and functional relationship or correlation between ALSP or pediatric-onset leukoencephalopathy in vivo and the normal non-human primates. It is unpredictable whether the increased levels of CSF1R protein detected in the frontal cortex of the normal non-human primates after being intravenously administered with an anti-TREM2 antibody or the AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody compared to a control IgG treatment can be obtained or applicable to individuals with ALSP or pediatric-onset leukoencephalopathy in vivo.
The specification fails to teach whether the subject with ALSP or pediatric-onset leukoencephalopathy can still synthesize or generate a functional CSF1R protein or have functional CSF1R signaling as in the normal non-human primates after being administered with an anti-TREM2 antibody or the AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody because ALSP or pediatric-onset leukoencephalopathy is caused by mutations in the CSF1R gene and have no functional CSF1R protein or CSF1R signaling. The specification fails to teach or provide support to demonstrate that administration of the claimed anti-TREM2 agonist antibody or the AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody can correct gene mutations in the CSF1R gene in the subject with ALSP or pediatric-onset leukoencephalopathy to generate a functional CSF1 protein or functional CSF1R signaling, and thereby treating ALSP or pediatric-onset leukoencephalopathy.
The claimed CSF1R-deficient diseases are defined and characterized as resulting from deficiencies or other defects in CSF1R signaling, or having a CSF1R protein with reduced function, or having a mutation in the CSF1R gene including a missense mutation, an indel, or a mutation generating a truncated protein product (see para. [0092] of the instant specification).
ALSP is caused by heterozygous dominant mutations in the CSF1R or gene genetic deficits or mutations in CSF1R gene leading to CSF1R deficiency (see para. [0097] of the instant specification), which does not have a functional CSF1R protein or functional CSF1R signaling (see p. 5053-5060; Chitu et al., The FEBS J, 2022; 289:5049-5073, cited previously), and thus results in development of skeletal dysplasia, brain disorder and developmental anomalies including ventriculomegaly and cerebellar atrophy, as well as leukodystrophy (see Dulski et al. CSF1R-Related Disorder. 2012 Aug 30 [Updated 2024 Apr 4]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026, cited previously) and Chitu et al., The FEBS J, 2022; 289:5049-5073, cited previously).
Pediatric-onset leukoencephalopathy is rare fatal neurological disease caused by homozygous mutations in the CSF1R gene leading to CSF1R deficiency (see para. [0103] of the instant specification), which does not have a functional CSF1R protein or functional CSF1R signaling (see p. 5053-5060; Chitu et al., The FEBS J, 2022; 289:5049-5073), and thus results in development of structural brain anomalies and almost complete absence of microglia (see Dulski et al. CSF1R-Related Disorder. 2012 Aug 30 [Updated 2024 Apr 4]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026) and Chitu et al. (The FEBS J, 2022; 289:5049-5073).
The specification provides no guidance as to whether patients with ALSP caused by genetic deficits or mutations in the CSF1R gene leading to CSF1R deficiency or pediatric-onset leukoencephalopathy caused by homozygous mutations in the CSF1R gene leading to CSF1R deficiency can still synthesize or generate a functional CSF1R protein or functional CSF1R signaling as the normal non-human primates or as detected in the frontal cortex of the normal non-human primates after being treated with the anti-TREM2 antibody: AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody, thereby treating ALSP or pediatric-onset leukoencephalopathy.
Thus, it is unpredictable whether administration of the anti-TREM2 antibody: AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody to an individual with ALSP or Pediatric-onset leukoencephalopathy can result in the same effects of increased levels of CSF1R protein in the frontal cortex as in the normal non-human primates after being intravenously administered with the anti-TREM2 antibody: AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody compared to treatment with a control IgG shown in Examples 3-4 of the instant specification.
ii. There is no well-established structural and functional relationship between the claimed anti-TREM2 agonist antibody with no defined structure and function and the AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody in increasing levels of CSF1R protein detected in the frontal cortex of the normal non-human primates after administration of the AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody compared to a control IgG treatment shown in Examples 3-4 or even in individuals with ALSP or pediatric-onset leukoencephalopathy in vivo.
The specification provides no well-established structural and functional relationship or correlation between treatment of ALSP or pediatric-onset leukoencephalopathy in vivo using a structurally and functionally undefined anti-TREM2 agonist antibody and the increased levels detected in samples isolated from the frontal cortex of the normal non-human primates after being intravenously administered with the AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody compared to treatment with a control IgG as shown in Examples 3-4 of the instant specification.
The specification fails to provide sufficient guidance as to what other anti-TREM2 agonist antibodies are and whether all anti-TREM2 agonist antibodies including anti-TREM2 agonist antibody binding 149-157 of SEQ ID NO:1 or TREM2 variants, binding one or more amino acid residues recited in claim 19 or an anti-TREM2 agonist antibody having recited SEQ ID NOs; 34-35, 31 and 41, 33 and 32 for HCDRs1-3 and LCDRs1-3 respectively or having SEQ ID NOs: 27 and 30 for VH and VL respectively or having SEQ ID NOs: 44 and 47 for HC and LC respectively can be used in the claimed method and treat ALSP or pediatric-onset leukoencephalopathy. There is no structural and functional relationship between the claimed anti-TREMs agonist antibody and the anti-TREM2 antibody AL2p-58 huIgG1 PSEG (comprising SEQ ID NOs: 43/44 and 47 for heavy chain and light chain as listed in Table B) or AL2p-58 HuIgG1 in increasing an expression level of CSF1R protein in samples isolated the frontal cortex and/or the hippocampus of the normal non-human primates after being administered with the AL2p-58 huIgG1 PSEG or AL2p-58 HuIgG1 antibody compared to the control IgG treatment or even in treatment of ALSP or pediatric-onset leukoencephalopathy in vivo.
The specification fails to teach what other structures/amino acid sequences can or cannot be included/changed in the claimed anti-TREM2 agonist antibodies in order to preserve the activity of anti-TREM2 antibody AL2p-58 huIgG1 PSEG (comprising SEQ ID NOs: 43/44 and 47 for heavy chain and light chain as listed in Table B) or AL2p-58 HuIgG1 in increasing an expression level of CSF1R protein in samples isolated the frontal cortex and/or the hippocampus of the normal non-human primates or even in treating ALSP or pediatric-onset leukoencephalopathy in vivo, indicating that undue experimentation is required by a skilled artisan to perform while practicing the claimed invention.
Thus, it is unpredictable whether administration of the claimed TREM2 agonist antibody with no defined structure or the TREM2 agonist antibody AL2p-58 huIgG1 PSEG or AL2p-58 HuIgG1 can treat ALSP or pediatric-onset leukoencephalopathy that are caused by genetic deficits or mutations in CSF1R gene in vivo, indicating that undue experimentation is required by a skilled artisan to perform while practicing the claimed invention.
Therefore, in view of the breadth of the claims, the lack of guidance in the specification, the lack of working examples, the unpredictability of inventions, and the current status of the art, undue experimentation would be required by one of skill in the art to perform in order to practice the claimed invention as it pertains to a method for treating a CSF1R-deficient disease by the claimed anti-TREM2 agonist antibody, wherein the CSF1R-deficient disease is ALSP or pediatric-onset leukoencephalopathy, or a method of monitoring a treatment of an individual with all possible conditions after being administered with the claimed anti-TREM2 agonist antibody.
Response to Arguments
On p. 14-17 of the response, Applicant argues that i) the rejection has been overcome in view of amendment to claim 1 by removing “or preventing” and reciting “wherein the CSF1R-deficient disease is …ALSP or pediatric-onset leukoencephalopathy”; ii) the specification provides support for the claimed method and cites para. [0093], Examples 1-4 and Teva Pharm. Intl. GmbH. v. Eli Lily & Co., para. [0187], [0188]-[0201], [0208]-[0220]; [0221]-[0226] and [0233]-[0255] of US20230024528 (published application) and MPEP2164.08 and MPEP2164.01(b) in support of the arguments.
Applicant's arguments filed 06/16/2026 have been fully considered but they are not found persuasive. Contrary to Applicant's arguments, the examiner asserts that based on MPEP §2164, MPEP §§2164.01-2164.06(b) & 2164.08, the specification provides insufficient guidance to enable a skilled artisan to practice the claimed methods without undue experimentation because:
i. There is no well-established structural and functional relationship or correlation between ALSP or pediatric-onset leukoencephalopathy in vivo and the normal non-human primates.
The specification fails to teach whether the subject with ALSP or pediatric-onset leukoencephalopathy can still synthesize or generate functional CSF1R protein as in the normal non-human primates after being administered with an anti-TREM2 agonist antibody or the AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody. Note that the subject with ALSP or pediatric-onset leukoencephalopathy has mutations in the CSF1R gene and has no functional CSF1 protein or functional CSF1R signaling. The specification fails to teach or provide support to demonstrate that administration of the claimed anti-TREM2 agonist antibody or the AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody can correct gene mutations in the CSF1R gene in the subject with ALSP or pediatric-onset leukoencephalopathy to generate a functional CSF1 protein or functional CSF1R signaling, and thereby treating ALSP or pediatric-onset leukoencephalopathy.
ALSP is caused by heterozygous dominant mutations in the CSF1R or gene genetic deficits or mutations in CSF1R gene leading to CSF1R deficiency (see para. [0097] of the instant specification), which do not have a functional CSF1R protein or functional CSF1R signaling. Pediatric-onset leukoencephalopathy is rare fatal neurological disease caused by homozygous mutations in the CSF1R gene leading to CSF1R deficiency (see para. [0103] of the instant specification), which do not have a functional CSF1R protein or functional CSF1R signaling.
It is not known whether administration of the AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody or the claimed structurally and functionally undefined anti-TREM2 antibody to subjects with ALSP or pediatric-onset leukoencephalopathy can result in increased levels of CSF1R protein in the frontal cortex of the normal non-human primates after being intravenously administered with the AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody when compared to a control IgG treatment, and thereby treating ALSP or pediatric-onset leukoencephalopathy.
ii. The specification provides no well-established structural and functional relationship or correlation between treatment of ALSP or pediatric-onset leukoencephalopathy in vivo using a structurally and functionally undefined anti-TREM2 agonist antibody and the increased levels detected in samples isolated from the frontal cortex of the normal non-human primates after being intravenously administered with an anti-TREM2 antibody: AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody compared to treatment with a control IgG as shown in Examples 3-4 of the instant specification.
The specification also fails to provide sufficient guidance as to what other anti-TREM2 agonist antibodies are and whether all anti-TREM2 agonist antibodies including anti-TREM2 agonist antibody binding 149-157 of SEQ ID NO:1 or TREM2 variants, binding one or more amino acid residues recited in claim 19 or an anti-TREM2 agonist antibody having recited SEQ ID NOs; 34-35, 31 and 41, 33 and 32 for HCDRs1-3 and LCDRs1-3 respectively or having SEQ ID NOs: 27 and 30 for VH and VL respectively or having SEQ ID NOs: 44 and 47 for HC and LC respectively can be used in the claimed method and treat ALSP or pediatric-onset leukoencephalopathy.
Thus, it is unpredictable whether administration of the claimed TREM2 agonist antibody with no defined structure or the TREM2 agonist antibody AL2p-58 huIgG1 PSEG or AL2p-58 HuIgG1 can treat ALSP or pediatric-onset leukoencephalopathy that are caused by genetic deficits or mutations in CSF1R gene in vivo, indicating that undue experimentation is required by a skilled artisan to perform while practicing the claimed invention.
iii. The scope of the claims must bear a reasonable correlation with the scope of enablement (In re Fisher, 166 USPQ 19 24 (CCPA 1970)). Without such guidance, it is unpredictable what changes can be made and still maintain activity; and thus the experimentation left to those skilled in the art is extensive and undue. See Ex parte Forman, 230 USPQ 546 (Bd. Pat. App. & Int. 1986). Thus, the skilled artisan cannot readily make and use the claimed invention as currently claimed without further undue experimentation. Note that
“The ‘predictability or lack thereof' in the art refers to the ability of one skilled in the art to extrapolate the disclosed or known results to the claimed invention. If one skilled in the art can readily anticipate the effect of a change within the subject matter to which the claimed invention pertains, then there is predictability in the art. On the other hand, if one skilled in the art cannot readily anticipate the effect of a change within the subject matter to which that claimed invention pertains, then there is lack of predictability in the art. Accordingly, what is known in the art provides evidence as to the question of predictability. In particular, the court in In re Marzocchi, 439 F.2d 220, 223-24, 169 USPQ 367, 369-70 (CCPA 1971)” See MPEP § 2164.03.
Further, a patent is granted for a completed invention, not the general suggestion of an idea and how that idea might be developed into the claimed invention. In the decision of Genentec, Inc, v. Novo Nordisk, 42 USPQ 2d 100,(CAFC 1997), the court held that:
“[p]atent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable” and that “[t]ossing out the mere germ of an idea does not constitute enabling disclosure”. The court further stated that “when there is no disclosure of any specific starting material or of any of the conditions under which a process is to be carried out, undue experimentation is required; there is a failure to meet the enablement requirements that cannot be rectified by asserting that all the disclosure related to the process is within the skill of the art”, “[i]t is the specification, not the knowledge of one skilled in the art, that must supply the novel aspects of an invention in order to constitute adequate enablement”.
The instant specification is not enabling because one cannot follow the guidance presented therein and practice the claimed method without first making a substantial inventive contribution.
Therefore, in view of the breadth of the claims, the lack of guidance in the specification, the lack of working examples, the unpredictability of inventions, and the current status of the art, undue experimentation would be required by one of skill in the art to perform in order to practice the claimed invention as it pertains to a method for treating a CSF1R-deficient disease by the claimed anti-TREM2 agonist antibody, wherein the CSF1R-deficient disease is ALSP or pediatric-onset leukoencephalopathy, or a method of monitoring a treatment of an individual with all possible conditions after being administered with the claimed anti-TREM2 agonist antibody.
Accordingly, the rejection of claims 1-11, 15-17, 19, 21, 25-29, 31, 35 and 42 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement is maintained.
Claim Rejections - 35 USC § 112
9. Claims 1-11, 15-17, 19, 21, 25-29, 31, 35 and 42 stand rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. The rejection is maintained for the reasons of record and the reasons set forth below.
Claims 1-11, 15-17, 19, 21, 25-29, 31, 35 and 42 as amended encompass using a genus of anti-TREM2 agonist antibodies for treating a CSF1R-deficient disease that is ALSP or pediatric-onset Leukoencephalopathy.
Claim 17 encompasses using a genus of bispecific anti-TREM2 agonist antibodies, multivalent anti-TREM2 agonist antibodies.
Claim 19 encompasses using a genus of anti-TREM2 agonist antibodies binding to TREM2 variants, or a genus of anti-TREM2 agonist antibodies binding to aa 149-157 of SEQ ID NO:1, one or more amino acid residues recited in claim 19.
Briefly, Applicant has not disclosed sufficient species for using the broad genus of anti-TREM2 agonist antibodies, the broad genus of bispecific anti-TREM2 agonist antibodies and multivalent anti-TREM2 agonist antibodies, the broad genus of anti-TREM2 agonist antibodies binding to aa 149-157 of SEQ ID NO:1, variants of TREM2, or one more amino acids recited in claim 20 or an anti-TREM2 agonist antibody having recited SEQ ID NOs; 34-35, 31 and 41, 33 and 32 for HCDRs1-3 and LCDRs1-3 respectively or having SEQ ID NOs: 27 and 30 for VH and VL respectively or having SEQ ID NOs: 44 and 47 for HC and LC respectively for treating ALSP or pediatric-onset Leukoencephalopathy.
The specification only disclosed that administration of the anti-TREM2 agonist antibody AL2p-58 huIgG1 PSEG antibody or AL2p-58 HuIgG1 antibody to normal non-human primates by intravenous injection for a total of five doses increased expression of CSF1R protein in samples isolated from the frontal cortex and/or hippocampus of the normal non-human primates compared to the samples isolated from the non-human primates treated with a control IgG.
The specification provides no well-established correlation between the normal non-human primates with no disease or gene deficits and ALSP that is caused by heterozygous mutation in CSF1R gene or pediatric-onset leukoencephalopathy caused by homozygous mutations in CSF1R gene in vivo.
The specification provides no well-established structural and functional relationship between the claimed genus of anti-TREMs agonist antibody and the anti-TREM2 antibody AL2p-58 huIgG1 PSEG (comprising SEQ ID NOs: 43/44 and 47 for heavy chain and light chain as listed in Table B) or AL2p-58 HuIgG1 in increasing the expression level of CSF1R protein in samples isolated the frontal cortex and/or the hippocampus of the normal non-human primates after being administered with the AL2p-58 huIgG1 PSEG or AL2p-58 HuIgG1 antibody compared to the samples isolated from the non-human primates treated with a control IgG or even in treatment of ALSP or pediatric-onset leukoencephalopathy which is caused by genetic deficit or heterozygous or homozygous mutations in CSF1R gene in vivo.
The specification fails to teach what other structures/amino acid sequences can or cannot not be included/changed in all anti-TREM2 agonist antibodies in order to preserve the activity of anti-TREM2 antibody AL2p-58 huIgG1 PSEG (comprising SEQ ID NOs: 43/44 and 47 for heavy chain and light chain as listed in Table B) or AL2p-58 HuIgG1 in increasing an expression level of CSF1R protein in samples isolated the frontal cortex and/or the hippocampus of the normal non-human primates or even in treating ALSP or pediatric-onset leukoencephalopathy caused by genetic deficit including mutations in CSF1R gene in vivo.
Furthermore, the prior art does not provide compensatory structural or correlative teachings sufficient to enable one of skill to identify what other anti-TREM2 agonist antibodies including bispecific, multivalent, binding to aa 149-157 or one or more amino acids recited in claim 19 or other anti-TREM2 antibody might be or whether administration of the anti-TREM2 agonist antibody having SEQ ID NOs; 34-35, 31 and 41, 33 and 32 for HCDRs1-3 and LCDRs1-3 respectively or having SEQ ID NOs: 27 and 30 for VH and VL respectively or having SEQ ID NOs: 44 and 47 for HC and LC respectively can treat ALSP or pediatric-onset leukoencephalopathy caused by genetic deficit including mutations in CSF1R gene in vivo.
Since the common characteristics/features of other anti-TREM2 agonist antibodies and treatment of ALSP or pediatric-onset leukoencephalopathy caused by genetic deficit including mutations in CSF1R gene in vivo are unknown, a skilled artisan cannot envision the functional correlations of the genus with the claimed invention.
Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of using the genus of anti-TREM2 agonist antibody for treating ALSP or pediatric-onset leukoencephalopathy caused by genetic deficit including mutations in CSF1R gene in vivo or using the genus of TREM2 agonist antibody for monitoring the treatment of an TREM2 agonist antibody based on measuring the level of CSF1R in a sample from an individual being administered the TREM2 agonist antibody.
Therefore, the claimed methods have not met the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115). Applicant is directed to the Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1 "Written Description" Requirement. See MPEP § 2161.01 and 2163.
Response to Arguments
On p. 17-18 of the response, Applicant argues that i) the rejection has been overcome for the reasons set forth above and cites MPEP2163 and Teva v. Lily in support of the arguments.
Applicant's arguments have been fully considered but they are not found persuasive. Contrary to Applicant's arguments, the examiner asserts that based on MPEP §2163, MPEP §§2163.01-2163.03, the specification fails to provide sufficient description or information or evidence to demonstrate that Applicant is in possession of using the claimed genus of anti-TREM2 agonist antibody for treating ALSP or pediatric-onset leukoencephalopathy or monitoring the treatment of an individual being administering with an anti-TREM2 agonist antibody based on measuring the level of CSF1R in a sample from the individual being administered the TREM2 agonist antibody. because:
i. The specification provides no well-established correlation between the normal non-human primates with no disease or gene deficits and ALSP that is caused by heterozygous mutation in CSF1R gene or pediatric-onset leukoencephalopathy caused by homozygous mutations in CSF1R gene in vivo.
The specification provides no well-established structural and functional relationship between the claimed genus of anti-TREMs agonist antibody and the anti-TREM2 antibody AL2p-58 huIgG1 PSEG (comprising SEQ ID NOs: 43/44 and 47 for heavy chain and light chain as listed in Table B) or AL2p-58 HuIgG1 in increasing the expression level of CSF1R protein in samples isolated the frontal cortex and/or the hippocampus of the normal non-human primates after being administered with the AL2p-58 huIgG1 PSEG or AL2p-58 HuIgG1 antibody compared to the samples isolated from the non-human primates treated with a control IgG, or even in treatment of ALSP or pediatric-onset leukoencephalopathy which is caused by genetic deficit or heterozygous or homozygous mutations in CSF1R gene in vivo.
ii. The specification fails to teach what other structures/amino acid sequences can or cannot not be included/changed in all anti-TREM2 agonist antibodies in order to preserve the activity of anti-TREM2 antibody AL2p-58 huIgG1 PSEG (comprising SEQ ID NOs: 43/44 and 47 for heavy chain and light chain as listed in Table B) or AL2p-58 HuIgG1 in increasing an expression level of CSF1R protein in samples isolated the frontal cortex and/or the hippocampus of the normal non-human primates or even in treating ALSP or pediatric-onset leukoencephalopathy caused by genetic deficit including mutations in CSF1R gene in vivo.
Since the common characteristics/features of other anti-TREM2 agonist antibodies and their effects on treatment of ALSP or pediatric-onset leukoencephalopathy caused by genetic deficit including mutations in CSF1R gene in vivo are unknown, a skilled artisan cannot envision the functional correlations of the genus with the claimed invention in view of Burgess et al. (J of Cell Bio. 1990, 111:2129-2138, cited previously), Bowie et al. (see col 2, p. 1306, Bowie et al. Science, 1990, 247:1306-1310, cited previously), Pawson et al. (see p. 445 the second column, first paragraph, Pawson et al. 2003, Science 300:445-452, cited previously), Alaoui-lsmaili et al. (see p. 502, right col., 2th paragraph; Alaoui-lsmaili et al., Cytokine Growth Factor Rev. 2009; 20:501-507, cited previously) and Guo et al. (see p. 9207, left col., 2th paragraph, Guo et al., PNAS 2004; 101:9205-9210, cited previously).
iii. As stated in M.P.E.P. § 2163(II)(A)(3), a specification may describe an actual reduction to practice by showing that the inventor constructed an embodiment or performed a process that met all the limitations of the claim and determined that the invention would work for its intended purpose. Cooper v. Goldfarb, 154 F.3d 1321,1327, 47 USPQ2d 1896, 1901 (Fed. Cir. 1998). See also UMC Elecs. Co. v. United States, 816 F.2d 647, 652, 2 USPQ2d 1465, 1468 (Fed. Cir. 1987) (“[T]here cannot be a reduction to practice of the invention ... without a physical embodiment which includes all limitations of the claim.”); Estee Lauder Inc. v. L’Oreal, S.A., 129 F.3d 588, 593, 44 USPQ2d 1610, 1614 (Fed. Cir. 1997) (“[A] reduction to practice does not occur until the inventor has determined that the invention will work for its intended purpose.”); Mahurkar v. C.R. Bard, Inc., 79 F.3d 1572, 1578, 38 USPQ2d 1288, 1291 (Fed. Cir. 1996) (determining that the invention will work for its intended purpose may require testing depending on the character of the invention and the problem it solves).
To demonstrate the reduction to practice of a method of treating an animal by the administration of an anti-TREM2 agonist antibody requires either a working embodiment, a demonstration of operability in the treatment of an art accepted animal model of the condition to be treated wherein that animal model has been shown to be reliably predictive of efficacy in the treatment of the condition, or a demonstration that the therapeutic agent employed therein possesses an activity in which the majority of compounds possessing that activity have been shown to be effective in the treatment of that condition. In the instant case, Applicant has provided none of these. Consequently, Applicant has failed to demonstrate possession of the claimed method or even using a single species of the genus of anti-TREM2 agonist antibody in the claimed method required thereby as of the earliest effective filing date of the instant application.
With respect to the demonstration of a reduction to practice of a generic invention, M.P.E.P. § 2163(II)(A)(3)(ii) states that the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus, above). See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406. A “representative number of species” means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. See AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 1285, 1300, 111 USPQ2d 1780, 1790 (Fed. Cir. 2014).
In the instant case, Applicant has failed to demonstrate a reduction to practice of using a representative number of species of the genus of “anti-TREM2 agonist antibody” for treating an animal model of ALSP or pediatric-onset leukoencephalopathy by the administration of the anti-TREM2 agonist antibody thereto.
The experimental results described in the specification consist primarily of the characterization of the anti-TREM2 antibody AL2p-58 huIgG1 PSEG (comprising SEQ ID NOs: 43/44 and 47 for heavy chain and light chain as listed in Table B) or AL2p-58 HuIgG1 in increasing the expression level of CSF1R protein in the frontal cortex and/or the hippocampus of the normal non-human primates after being administered with the AL2p-58 huIgG1 PSEG or AL2p-58 HuIgG1 antibody as compared to the a control IgG treatment. Those results do not support a conclusion that Applicant was in possession of a method of treating ALSP or pediatric-onset leukoencephalopathy caused by genetic deficit including mutations in CSF1R gene in vivo by the administration thereto of an anti-TREM2 agonist antibody because subjects with ALSP or pediatric-onset leukoencephalopathy caused by heterozygous or homozygous mutations in CSF1R gene have no functional CSF1R protein or CSF1R signaling in vivo. The specification provides no well-established correlation between the normal non-human primates with no disease or gene deficits and ALSP that is caused by heterozygous mutation in CSF1R gene or pediatric-onset leukoencephalopathy caused by homozygous mutations in CSF1R gene in vivo.
Based on MPEP § 2161.01 and §2163, “to satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. See, e.g., Moba, B.V. v. Diamond Automation, Inc., 325 F.3d 1306, 1319, 66 USPQ2d 1429, 1438 (Fed. Cir. 2003); Vas-Cath, Inc. v. Mahurkar, 935 F.2d at 1563, 19 USPQ2d at 1116”.
Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See Vas-Cath at page 1116).
As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of anti-TREM2 agonist antibodies and their effects on treatment of ALSP or pediatric-onset leukoencephalopathy caused by genetic deficit including mutations in CSF1R gene in vivo, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See Fiers v. Revel, 25 USPQ2d 1601 at 1606 (CAFC 1993) and Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. One cannot describe what one has not conceived. See Fiddes v. Baird, 30 USPQ2d 1481 at 1483.
Therefore, the claimed methods have not met the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115). Applicant is directed to the Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1 "Written Description" Requirement. See MPEP § 2161.01 and 2163.
Accordingly, the rejection of claims 1-11, 15-17, 19, 21, 25-29, 31, 35 and 42 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement is maintained.
Conclusion
10. NO CLAIM IS ALLOWED.
11. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
Schwabe et al. (US2019040130, as in IDS) teach a method of treating different diseases including multiple sclerosis ([0439]-[0442]), comprising administering to a subject in need thereof a therapeutically effective amount of an anti-TREM2 agonist antibody to induce one or more TREM2 activities including DAP12 phosphorylation, PI3K activation, increased expression of one more anti-inflammatory mediators and reduced expression of one or more pro-inflammatory mediations (see para. [0442])), wherein the anti-TREM2 agonist antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 201, which is 100% identical to instant SEQ ID NO:44, and a light chain comprising the amino acid sequence of SEQ ID NO:214, which is 100% identical to instant SEQ ID NO:47 recited in claim 29 (see the sequence alignment below; see para.[0027]; [0105]-[0128], [0261]; [0254]-[0279]; claim 40).
SEQ ID NO:44
BGB58142
(NOTE: this sequence has 9 duplicates in the database searched)
ID BGB58142 standard; protein; 452 AA.
XX
AC BGB58142;
XX
DT 21-MAR-2019 (first entry)
XX
DE Anti-TREM2 antibody HC region-mutant huIgG1 PSEG, SEQ ID 201.
XX
KW TREM2 protein; alzheimers disease; amnesia; antibody;
KW antibody production; antibody therapy; antiinflammatory; cancer;
KW cognitive disorder; colitis; cytostatic; dementia;
KW frontotemporal dementia; gastrointestinal-gen.; heavy chain;
KW immunoglobulin G1; immunoglobulin gamma 1; immunosuppressive;
KW multiple sclerosis; mutein; neuroprotective; nootropic;
KW prophylactic to disease; spinal cord injury; therapeutic;
KW traumatic brain injury; triggering receptor expressed on myeloid cells-2;
KW ulcerative colitis; vulnerary.
XX
OS Homo sapiens.
OS Unidentified.
OS Chimeric.
OS Synthetic.
XX
CC PN US2019040130-A1.
XX
CC PD 07-FEB-2019.
XX
CC PF 03-AUG-2018; 2018US-00054680.
XX
PR 03-AUG-2017; 2017US-0541019P.
PR 27-FEB-2018; 2018US-0636095P.
XX
CC PA (ALEC-) ALECTOR LLC.
XX
CC PI Schwabe T, Brown E, Kong P, Tassi I, Lee S, Rosenthal A;
CC PI Pejchal R, Nielson NP;
XX
DR WPI; 2019-13815K/17.
XX
CC PT New antibody useful in pharmaceutical composition for preventing,
CC PT reducing risk, or treating individual having disease, disorder or injury
CC PT including dementia, frontotemporal dementia, Alzheimer's disease,
CC PT cognitive deficit and memory loss.
XX
CC PS Claim 13; SEQ ID NO 201; 264pp; English.
XX
CC The present invention relates to a novel anti-triggering receptor
CC expressed on myeloid cells-2 (TREM2) antibody useful for preparing a
CC pharmaceutical composition. The pharmaceutical composition is used for
CC preventing, reducing risk or treating individual having disease, disorder
CC or injury includes dementia, frontotemporal dementia, Alzheimer's
CC disease, Nasu-Hakola disease, cognitive deficit, memory loss, spinal cord
CC injury, traumatic brain injury, multiple sclerosis, chronic colitis,
CC ulcerative colitis and cancer. The invention further provides: a nucleic
CC acid sequence encoding the antibody; a vector comprising the nucleic acid
CC ; an isolated host cell comprising the vector; a method of producing the
CC antibody that binds to TREM2; and an antibody comprising fragment
CC crystallizable (Fc) region. The present sequence represents a anti-TREM2
CC antibody heavy chain region (HC) comprising a mutant human immunoglobulin
CC gamma 1 (huIgG1 PSEG) P331S/E430G, which is used in the invention for
CC treating the above mentioned diseases.
XX
SQ Sequence 452 AA;
Query Match 100.0%; Score 2407; Length 452;
Best Local Similarity 100.0%;
Matches 452; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYAFSSQWMNWVRQAPGQRLEWIGRIYPGGGDTNY 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYAFSSQWMNWVRQAPGQRLEWIGRIYPGGGDTNY 60
Qy 61 AGKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCARLLRNQPGESYAMDYWGQGTLVT 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 AGKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCARLLRNQPGESYAMDYWGQGTLVT 120
Qy 121 VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL 180
Qy 181 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL 240
Qy 241 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE 300
Qy 301 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPS 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPS 360
Qy 361 RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK 420
Qy 421 SRWQQGNVFSCSVMHGALHNHYTQKSLSLSPG 452
||||||||||||||||||||||||||||||||
Db 421 SRWQQGNVFSCSVMHGALHNHYTQKSLSLSPG 452
SEQ ID NO:47
BGB58155
(NOTE: this sequence has 11 duplicates in the database searched)
ID BGB58155 standard; protein; 219 AA.
XX
AC BGB58155;
XX
DT 21-MAR-2019 (first entry)
XX
DE Anti-TREM2 antibody LC region-mutant huIgG1 PSEG, SEQ ID 214.
XX
KW TREM2 protein; alzheimers disease; amnesia; antibody;
KW antibody production; antibody therapy; antiinflammatory; cancer;
KW cognitive disorder; colitis; cytostatic; dementia;
KW frontotemporal dementia; gastrointestinal-gen.; immunoglobulin G1;
KW immunoglobulin gamma 1; immunosuppressive; light chain;
KW multiple sclerosis; mutein; neuroprotective; nootropic;
KW prophylactic to disease; spinal cord injury; therapeutic;
KW traumatic brain injury; triggering receptor expressed on myeloid cells-2;
KW ulcerative colitis; vulnerary.
XX
OS Homo sapiens.
OS Unidentified.
OS Chimeric.
OS Synthetic.
XX
CC PN US2019040130-A1.
XX
CC PD 07-FEB-2019.
XX
CC PF 03-AUG-2018; 2018US-00054680.
XX
PR 03-AUG-2017; 2017US-0541019P.
PR 27-FEB-2018; 2018US-0636095P.
XX
CC PA (ALEC-) ALECTOR LLC.
XX
CC PI Schwabe T, Brown E, Kong P, Tassi I, Lee S, Rosenthal A;
CC PI Pejchal R, Nielson NP;
XX
DR WPI; 2019-13815K/17.
XX
CC PT New antibody useful in pharmaceutical composition for preventing,
CC PT reducing risk, or treating individual having disease, disorder or injury
CC PT including dementia, frontotemporal dementia, Alzheimer's disease,
CC PT cognitive deficit and memory loss.
XX
CC PS Claim 13; SEQ ID NO 214; 264pp; English.
XX
CC The present invention relates to a novel anti-triggering receptor
CC expressed on myeloid cells-2 (TREM2) antibody useful for preparing a
CC pharmaceutical composition. The pharmaceutical composition is used for
CC preventing, reducing risk or treating individual having disease, disorder
CC or injury includes dementia, frontotemporal dementia, Alzheimer's
CC disease, Nasu-Hakola disease, cognitive deficit, memory loss, spinal cord
CC injury, traumatic brain injury, multiple sclerosis, chronic colitis,
CC ulcerative colitis and cancer. The invention further provides: a nucleic
CC acid sequence encoding the antibody; a vector comprising the nucleic acid
CC ; an isolated host cell comprising the vector; a method of producing the
CC antibody that binds to TREM2; and an antibody comprising fragment
CC crystallizable (Fc) region. The present sequence represents a anti-TREM2
CC antibody light chain region (LC) comprising a mutant human immunoglobulin
CC gamma 1 (huIgG1 PSEG) P331S/E430G, which is used in the invention for
CC treating the above mentioned diseases.
XX
SQ Sequence 219 AA;
Query Match 100.0%; Score 1137; Length 219;
Best Local Similarity 100.0%;
Matches 219; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 DVVMTQSPDSLAVSLGERATINCRSSQSLVHSNRYTYLHWYQQKPGQSPKLLIYKVSNRF 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 DVVMTQSPDSLAVSLGERATINCRSSQSLVHSNRYTYLHWYQQKPGQSPKLLIYKVSNRF 60
Qy 61 SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTRVPYTFGQGTKLEIKRTVAAPSV 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTRVPYTFGQGTKLEIKRTVAAPSV 120
Qy 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
Qy 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
|||||||||||||||||||||||||||||||||||||||
Db 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
12. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHANG-YU WANG whose telephone number is (571)272-4521. The examiner can normally be reached Monday-Thursday, 7:00am-5:00pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at 571-272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Chang-Yu Wang
September 10, 2026
/CHANG-YU WANG/Primary Examiner, Art Unit 1675